Cadralazine Did Not Produce the SLE-syndrome when Hydralazine Did

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1987 Jan 1

PMID 3556384

Citations 4

Authors

O K Andersson

Affiliations

Soon will be listed here.

Citing Articles

Conversion of drug-induced SLE-syndrome by the vasodilating agent cadralazine.

Mulder H Eur J Clin Pharmacol. 1990; 38(3):303.

PMID: 2340851 DOI: 10.1007/BF00315036.

Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

McTavish D, Young R, Clissold S Drugs. 1990; 40(4):543-60.

PMID: 2083513 DOI: 10.2165/00003495-199040040-00005.

Inhibition of complement components C3 and C4 by cadralazine and its active metabolite.

Andersson M, Hanson A, Englund G, Dahlback B Eur J Clin Pharmacol. 1991; 40(3):261-5.

PMID: 2060562 DOI: 10.1007/BF00315206.

Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.

Caponnetto S, Valvo E, Mocarelli P, Alberti D, Savonitto S Eur J Clin Pharmacol. 1991; 40(5):461-5.

PMID: 1679390 DOI: 10.1007/BF00315223.

References

Catalano M, Parini J, Romano M, LIBRETTI A . Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension. Eur J Clin Pharmacol. 1985; 28(2):135-8. DOI: 10.1007/BF00609680. View

Parravicini F, Scarpitta G, DORIGOTTI L, PIFFERI G . [3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes]. Farmaco Sci. 1979; 34(4):299-310. View